Affiliation:
1. Department of Microbiology, Kyoto Pharmaceutical University, Japan.
Abstract
The in vitro activity of Q-35, an 8-methoxy fluoroquinolone, was compared with those of ofloxacin, ciprofloxacin, tosufloxacin, lomefloxacin, and sparfloxacin. The MICs of Q-35 for 90% of strains tested (MIC90s) of Staphylococcus aureus, methicillin-resistant S. aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, and Streptococcus pyogenes were 0.2, 6.25, 0.2, 0.39, and 0.39 micrograms/ml, respectively. The activity of Q-35 was 4- to 16-fold greater than those of ofloxacin, ciprofloxacin and lomefloxacin but equal to those of tosufloxacin and sparfloxacin against these organisms. For 82 ciprofloxacin-resistant staphylococci (MIC90 = 100 micrograms/ml), Q-35 was the most active of the new quinolones tested (MIC90 = 6.25 micrograms/ml). The MIC90s of Q-35 against Escherichia coli, Enterobacter aerogenes, and Pseudomonas aeruginosa were 0.2, 0.78, and 12.5 micrograms/ml, respectively, and Q-35 was 2- to 16-fold less active than the other quinolones tested. Q-35 showed potent bactericidal activity and inhibited the supercoiling activity of DNA gyrase of S. aureus, E. coli, and P. aeruginosa.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference15 articles.
1. Revision of minimal inhibitory concentration (MIC) determination method;Committee for Revision of MIC Determination Method.;Chemotherapy (Tokyo),1981
2. In vitro activity of ciprofloxacin (Bay o 9867);Fass R. J.;Antimicrob. Agents Chemother.,1983
3. In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone;Fujimaki K.;Antimicrob. Agents Chemother.,1988
4. DNA gyrase: an enzyme that introduced superhelical turns into DNA;Gellert M.;Proc. Natl. Acad. Sci. USA,1976
5. In vitro and in vivo activity of NY-198, a new difluorinated quinolone;Hirose T.;Antimicrob. Agents Chemother.,1987
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献